Company Kangstem Biotech Co., Ltd.

Equities

A217730

KR7217730001

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sector Other Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-16 EDT			5-day change	1st Jan Change
2,320 ^KRW	-4.13%		-10.25%	-3.13%

04-25	An undisclosed buyer agreed to acquire a 24.27% stake in Croen Inc. from Kangstem Biotech Co., Ltd. for KRW 2.8 billion	CI
2023	Kangstem Biotech Co., Ltd.(KOSDAQ:A217730) dropped from S&P Global BMI Index	CI

Kang Stem Biotech Co., LTD is a Korea-based company mainly engaged in the development of pharmaceutical products. The Company's product portfolio consists of stem cell therapy products including Furestem-AD which used for treating atopic dermatitis, Furestem-RA which used for treating rheumatoid arthritis, Furestem-CD which used for treating crohnâs disease, stem cell conditioned medias which used as raw materials of cosmetics including umbilical cord blood-derived stem cell conditioned medias (USC-CMs) and others and stem cell culture medias including KSB-3 Complete Kit and others. The Company distributes its products within domestic market and to overseas markets.

Number of employees: 115

KRW in Million	2022	Weight	2023	Weight	Delta
Non-clinical Trial 53.5 %	10,386	63.7 %	6,791	53.5 %	-34.61%
Cosmetics 32.4 %	4,009	24.6 %	4,117	32.4 %	+2.69%
Stem Cell 11.4 %	1,343	8.2 %	1,444	11.4 %	+7.54%
Biopharma 2.8 %	563	3.5 %	351	2.8 %	-37.54%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 100.0 %	16,301	100.0 %	12,704	100.0 %	-22.06%

Managers	Title	Age	Since
Jong-Chun Na CEO	Chief Executive Officer	61	-
Seung-Hee Lee CTO	Chief Tech/Sci/R&D Officer	43	-
Seung-Won Im AUD	Comptroller/Controller/Auditor	64	-
Myung-Kwan Seo PRN	Corporate Officer/Principal	61	-

Members of the board	Title	Age	Since
Yong-Ho Park BRD	Director/Board Member	68	-
Jung-Ho Choi BRD	Director/Board Member	63	-
Sang-Kyun Lee BRD	Director/Board Member	71	-
Yo-Han Bae BRD	Director/Board Member	56	-
Jong-Chun Na CEO	Chief Executive Officer	61	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	67,499	0	0	85.70 %
Stock B	1	55,937,925	47,937,111 ( 85.70 %)	0

Name	Equities	%	Valuation
Hyung-Jin Kim 14.30 %	8,000,000	14.30 %	15 M ₩
Kyung-Sun Kang 4.699 %	2,628,526	4.699 %	5 M ₩
Jung-Ho Choi 0.3491 %	195,283	0.3491 %	372 311 ₩
Shin-hyun Kim 0.2081 %	116,415	0.2081 %	221 948 ₩
Jong-Chun Na 0.1461 %	81,729	0.1461 %	155 818 ₩
Kyung-hwan Roh 0.1359 %	76,000	0.1359 %	144 896 ₩
Dong-yeol Lee 0.1341 %	75,000	0.1341 %	142 989 ₩
Sang-Kyun Lee 0.1201 %	67,167	0.1201 %	128 055 ₩
Mi-hye Lee 0.0838 %	46,872	0.0838 %	89 362 ₩
Young-min Kang 0.0559 %	31,283	0.0559 %	59 642 ₩

KANGSTEM BIOTECH Co., Ltd.

17/F, Shinan Building 512 Teheran-ro

06179, Seoul

http://www.kangstem.com

address Kangstem Biotech Co., Ltd.(A217730)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
KANGSTEM BIOTECH CO., LTD.	-3.13%	95.91M
MODERNA, INC.	+36.76%	50.93B
IQVIA HOLDINGS INC.	-0.56%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+12.44%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-22.72%	18.9B
BIO-TECHNE CORPORATION	+7.88%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.67%	12.17B
MEDPACE HOLDINGS, INC.	+29.17%	12.16B

Other Biotechnology & Medical Research